Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of additional years of healthy life globally. Some examples of disease areas in which ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Brisbane won their opening match of the trials 46-20 against the Cowboys before a second-string side beat Manly 20-14 the following week to lock in a perfect record. Joshua Mayne is a content ...